Hematopoietic stem-cell transplantation for Hodgkin's disease (HD): current status

Cytotherapy
Paolo Anderlini

Abstract

Not all patients with Hodgkin's disease (HD) respond to standard chemotherapy and/or radiation, and hematopoietic stem-cell transplantation has been gaining increasing acceptance in the management of HD. Phase II and, to a lesser extent, phase III studies of high-dose chemotherapy and autologous stem cell transplantation carried out at multiple institutions worldwide have proven the feasibility of the procedure and provided extended progression-free survival (and possibly cure) in a sizable number of patients with relapsed or refractory HD. Prognostic factors have been identified by multiple investigators (with response to chemotherapy being the most impressive one) and may ultimately allow a risk-adapted strategy. While early and late treatment-related morbidity and mortality remains an issue, with current supportive care modalities most patients tolerate this procedure with only minor or manageable complications. Disease recurrence remains a problem in many patients, and this can unfortunately occur as late as six or seven years after a seemingly successful transplant. New chemotherapeutic agents and strategies (such as post-transplant maintenance and possibly immunomodulation) will be required to successfully tackle this iss...Continue Reading

References

Mar 5, 1992·The New England Journal of Medicine·W J Urba, D L Longo
Oct 26, 1999·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·A NademaneeS J Forman
Jul 25, 2000·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·L J Johnston, S J Horning
Jun 5, 2002·Cytotherapy·J M Vose

Related Concepts

Graft-vs-Host Disease
Hodgkin Lymphoma, Lymphocyte Depletion
Relapse
Transplantation, Autologous
Transplantation, Homologous
Controlled Clinical Trials, Randomized
Phase 3 Clinical Trials
Hemopoietic Stem Cell Transplant
Progression-Free Survival
Transplantation Conditioning

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.